Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy ( ICE) before Autologous Transplantation. Final Analysis of Phase II Study

被引：17
|
作者：
Stamatoullas, Aspasia [1 ]
Ghesquieres, Herv [2 ]
Filliatre, Lauriane Clement [3 ]
Quittet, Philippe [4 ]
Morschhauser, Franck [5 ]
Ribrag, Vincent [6 ]
Edeline, Veronique [7 ]
Brice, Pauline [8 ]
机构：
[1] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[2] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France
[3] CHRU, Vandoeuvre Les Nancy, France
[4] CHU St Eloi, Dept Hematol, Montpellier, France
[5] Hop Claude Huriez, CHRU Lille, Lille, France
[6] Gustave Roussy, Villejuif, France
[7] Hop Rene Huguenin, Inst Curie, Serv Med Nucl, St Cloud, France
[8] Hop St Louis, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123925
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
132
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma
    Ibrahim, D
    Smith, MR
    Varterasian, M
    Karanes, C
    Millenson, M
    Yeslow, G
    Pemberton, P
    Lai, P
    Abrams, J
    Al-Katib, A
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2079 - 2084
  • [32] Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
    Lynch, Ryan C.
    Cassaday, Ryan D.
    Smith, Stephen D.
    Fromm, Jonathan R.
    Cowan, Andrew J.
    Warren, Edus H.
    Shadman, Mazyar
    Shustov, Andrei R.
    Till, Brian G.
    Ujjani, Chaitra S.
    Libby, Edward
    Philip, Mary
    Coye, Hilary
    Martino, Christen N.
    Kanan, Sandra
    Morris, Karolyn K.
    Rasmussen, Heather A.
    Behnia, Sanaz
    Nartea, Margaret E.
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    BLOOD, 2020, 136
  • [33] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Moussab Damlaj
    Khadega A. Abuelgasim
    Ayman Alhejazi
    Bader Alahmari
    Ahmed Alaskar
    Mohsen Alzahrani
    Bone Marrow Transplantation, 2020, 55 : 2322 - 2325
  • [34] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Damlaj, Moussab
    Abuelgasim, Khadega A.
    Alhejazi, Ayman
    Alahmari, Bader
    Alaskar, Ahmed
    Alzahrani, Mohsen
    BONE MARROW TRANSPLANTATION, 2020, 55 (12) : 2322 - 2325
  • [35] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [36] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
  • [37] Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies
    Forero-Torres, Andres
    Fanale, Michelle
    Advani, Ranjana
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Kennedy, Dana A.
    Younes, Anas
    ONCOLOGIST, 2012, 17 (08): : 1073 - 1080
  • [38] Secondary malignancies in patients with relapsed or refractory Hodgkin's lymphoma treated with an autologous stem cell transplantation. An analysis of the lymphoma WP of the EBMT
    Sieniawski, M.
    Josting, A.
    Canals, C.
    Goldstone, A.
    Gramatzki, M.
    Blaise, D.
    Gisselbrecht, C.
    Crawley, C.
    Colombat, P.
    Harousseau, J.
    Johnson, P.
    Carella, A.
    Sureda, A.
    Socie, G.
    Schmitz, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 121 - 121
  • [39] Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Klasa, Richard
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2010, 116 (21) : 128 - 129
  • [40] Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
    Evens, Andrew M.
    Advani, Ranjana H.
    Helenowski, Irene B.
    Fanale, Michelle
    Smith, Sonali M.
    Jovanovic, Borko D.
    Bociek, Gregory R.
    Klein, Andreas K.
    Winter, Jane N.
    Gordon, Leo I.
    Hamlin, Paul A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 3015 - +
12345